{"id":"W4403012565","doi":"10.1016/s1470-2045(24)00190-6","title":"A brave new framework for glioma drug development","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Medac; Daiichi Sankyo Europe; National Cancer Institute; Servier; Seagen; University of Oxford; Sanofi; Apollomics; Innovent Biologics; Pfizer; Incyte; AstraZeneca; Novocure; Advanced Accelerator Applications; Voyager Therapeutics; Regeneron Pharmaceuticals; National Institutes of Health; Sage Therapeutics; Australian Government; Varian Medical Systems; ViewRay; Les Laboratories Pierre Fabre; Congress of Neurological Surgeons; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Glioma; Drug development; Drug; Computer science; Medicine; Pharmacology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00267334,0.001441762,0.002860108,0.002557022,0.0004904617,0.00299866,0.001622782,0.003262749,0.01106387],"category_scores_gemma":[0.00266903,0.0004909,0.001104046,0.002252555,0.001611053,0.004876461,0.00197825,0.005834911,0.004384849],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002293898,"about_ca_system_score_gemma":0.003665429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002539789,"about_ca_topic_score_gemma":0.006315642,"domain_scores_codex":[0.9992249,0.0002647451,0.00007338243,0.00008837254,0.0002392475,0.0001092974],"domain_scores_gemma":[0.9984272,0.0009598144,0.0001540365,0.00004645295,0.0002953522,0.0001172677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002290699,0.00009406319,0.00009982054,0.02093875,0.0002079108,0.0002092252,0.00009517888,0.0008689138,0.001247835,0.03788176,0.1696017,0.7685259],"study_design_scores_gemma":[0.00007402871,0.0001049568,0.0001250613,0.004608291,0.0001014642,0.0001894539,0.00004311716,0.0001234322,0.0001038882,0.009292342,0.9852182,0.00001576822],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004841937,0.9941618,0.0002705147,0.002890047,0.0009932728,0.000007105586,0.00004184433,0.00002249147,0.001564496],"genre_scores_gemma":[0.0009589781,0.9929671,0.0005122682,0.003439778,0.0007695599,0.00001493401,0.00006278147,0.00000679871,0.001267738],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01106387,"threshold_uncertainty_score":0.03701234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1524544275198428,"score_gpt":0.4490390022946686,"score_spread":0.2965845747748259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}